<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd"><id>2962035</id><setSpec>journal_article</setSpec><setSpec>doc-type:article</setSpec><setSpec>ddc:590</setSpec><setSpec>journal_articleFtxt</setSpec><setSpec>open_access</setSpec>

<genre>article</genre>

<titleInfo><title>Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?</title></titleInfo>


<note type="publicationStatus">published</note>


<note type="qualityControlled">yes</note>

<name type="personal">
  <namePart type="given">Constanze</namePart>
  <namePart type="family">Banz-Jansen</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Laureen P</namePart>
  <namePart type="family">Helweg</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Barbara</namePart>
  <namePart type="family">Kaltschmidt</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">7702352</identifier></name>







<name type="corporate">
  <namePart/>
  <identifier type="local">2685187</identifier>
  <role>
    <roleTerm type="text">department</roleTerm>
  </role>
</name>








<abstract lang="eng">Endometrial cancer is one of the most common malignant diseases in women worldwide, with an incidence of 5.9%. Thus, it is the most frequent cancer of the female genital tract, with more than 34,000 women dying, in Europe and North America alone. Endometrial Cancer Stem Cells (CSC) might be drivers of carcinogenesis as well as metastatic and recurrent disease. Therefore, targeting CSCs is of high interest to improve prognosis of patients suffering of advanced or recurrent endometrial cancer. This review describes the current evidence of molecular mechanisms in endometrial CSCs with special emphasis on MYC and NF-kappaB signaling as well as mitochondrial metabolism. Furthermore, the current status of immunotherapy targeting PD-1 and PD-L1 in endometrial cancer cells and CSCs is elucidated. The outlined findings encourage novel therapies that target signaling pathways in endometrial CSCs as well as immunotherapy as a promising therapeutic approach in the treatment of endometrial cancer to impede cancer progression and prevent recurrence. </abstract>

<relatedItem type="constituent">
  <location>
    <url displayLabel="ijms-23-03412-v2.pdf">https://pub.uni-bielefeld.de/download/2962035/2962284/ijms-23-03412-v2.pdf</url>
  </location>
  <physicalDescription><internetMediaType>application/pdf</internetMediaType></physicalDescription>
  <accessCondition type="restrictionOnAccess">no</accessCondition>
</relatedItem>
<originInfo><publisher>MDPI</publisher><dateIssued encoding="w3cdtf">2022</dateIssued>
</originInfo>
<language><languageTerm authority="iso639-2b" type="code">eng</languageTerm>
</language>

<subject><topic>endometrial cancer</topic><topic>cancer stem cells</topic><topic>endometrial cancer stem cells</topic><topic>MYC</topic><topic>NF-κB</topic><topic>PD-1</topic><topic>PD-L1</topic><topic>mitochondria</topic>
</subject>


<relatedItem type="host"><titleInfo><title> International Journal of Molecular Sciences</title></titleInfo>
  <identifier type="eIssn">1422-0067</identifier>
  <identifier type="MEDLINE">35328833</identifier><identifier type="urn">urn:nbn:de:0070-pub-29620356</identifier><identifier type="doi">10.3390/ijms23063412</identifier>
<part><detail type="volume"><number>23</number></detail><detail type="issue"><number>6</number></detail>
</part>
</relatedItem>


<extension>
<bibliographicCitation>
<mla>Banz-Jansen, Constanze, Helweg, Laureen P, and Kaltschmidt, Barbara. “Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?”. &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt; 23.6 (2022): 3412.</mla>
<frontiers>Banz-Jansen, C., Helweg, L. P., and Kaltschmidt, B. (2022). Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go? &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt; 23:3412.</frontiers>
<apa_indent>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Banz-Jansen, C., Helweg, L. P., &amp;amp; Kaltschmidt, B. (2022). Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go? &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt;, &lt;em&gt;23&lt;/em&gt;(6), 3412. &lt;a href="https://doi.org/10.3390/ijms23063412" target="_blank"&gt;https://doi.org/10.3390/ijms23063412&lt;/a&gt;&lt;/div&gt;</apa_indent>
<wels>Banz-Jansen, C.; Helweg, L. P.; Kaltschmidt, B. (2022): Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go? &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt;,23:(6):3412</wels>
<default>Banz-Jansen C, Helweg LP, Kaltschmidt B (2022) &lt;br /&gt;&lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt; 23(6): 3412.</default>
<ieee> C. Banz-Jansen, L.P. Helweg, and B. Kaltschmidt, “Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?”, &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt;,  vol. 23, 2022, : 3412.</ieee>
<harvard1>Banz-Jansen, C., Helweg, L.P., &amp;amp; Kaltschmidt, B., 2022. Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go? &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt;, 23(6): 3412.</harvard1>
<apa>Banz-Jansen, C., Helweg, L. P., &amp;amp; Kaltschmidt, B. (2022). Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go? &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt;, &lt;em&gt;23&lt;/em&gt;(6), 3412. &lt;a href="https://doi.org/10.3390/ijms23063412" target="_blank"&gt;https://doi.org/10.3390/ijms23063412&lt;/a&gt;</apa>
<dgps>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Banz-Jansen, C., Helweg, L.P. &amp;amp; Kaltschmidt, B. (2022). Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go? &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt;, &lt;em&gt;23&lt;/em&gt;(6): 3412. MDPI. doi:10.3390/ijms23063412.&lt;/div&gt;</dgps>
<bio1>Banz-Jansen C, Helweg LP, Kaltschmidt B (2022) &lt;br /&gt;Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?&lt;br /&gt; International Journal of Molecular Sciences 23(6): 3412.</bio1>
<angewandte-chemie>C.  Banz-Jansen, L. P.  Helweg, and B.  Kaltschmidt, “Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?”, &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt;, &lt;strong&gt;2022&lt;/strong&gt;, &lt;em&gt;23&lt;/em&gt;, : 3412.</angewandte-chemie>
<ama>Banz-Jansen C, Helweg LP, Kaltschmidt B. Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go? &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt;. 2022;23(6): 3412.</ama>
<lncs> Banz-Jansen, C., Helweg, L.P., Kaltschmidt, B.: Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?  International Journal of Molecular Sciences. 23, : 3412 (2022).</lncs>
<chicago>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Banz-Jansen, Constanze, Helweg, Laureen P, and Kaltschmidt, Barbara. 2022. “Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?”. &lt;em&gt; International Journal of Molecular Sciences&lt;/em&gt; 23 (6): 3412.&lt;/div&gt;</chicago>
</bibliographicCitation>
</extension>
<recordInfo><recordIdentifier>2962035</recordIdentifier><recordCreationDate encoding="w3cdtf">2022-03-28T10:10:47Z</recordCreationDate><recordChangeDate encoding="w3cdtf">2022-04-07T06:38:53Z</recordChangeDate>
</recordInfo>
</mods>